Perceptive Advisors’s Exagen XGN Stock Holding History

Perceptive Advisors’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$534K	Hold	114,893	–	–	0.01%	107
2026 Q1	$345K	Buy	+114,893	New	+$444K	0.01%	92

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Perceptive Advisors's XGN Position: Q2 2026 in Review

Perceptive Advisors held its Exagen (XGN) position steady in Q2 2026 at 114,893 shares worth $534K. The position accounts for 0.01% of the portfolio, ranked #107.

Perceptive Advisors first reported a position in XGN in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Perceptive Advisors held 114,893 shares of Exagen worth $534K as of Q2 2026.
Perceptive Advisors left its Exagen share count unchanged in Q2 2026.
Exagen made up 0.01% of Perceptive Advisors's portfolio in Q2 2026, its #107 holding.
Perceptive Advisors first reported a position in Exagen in Q1 2026 and has held it in 2 quarters since.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.